Semaglutide
Explore the science, structure, and potential of today’s most studied research compounds.
Overview
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It is a synthetic analog of endogenous GLP-1, modified to resist degradation and extend half-life, making it suitable for once-weekly subcutaneous administration.
Semaglutide enhances insulin secretion, inhibits glucagon release, delays gastric emptying, and reduces appetite—all contributing to improved glycemic control and weight loss.
Potential Benefits
1. Glycemic Control
-
In adults with type 2 diabetes, Semaglutide has been shown to reduce HbA1c levels by 1.4% to 1.8% depending on dose and baseline values.
-
Improvements occur even in patients already on other antidiabetic medications.
2. Weight Loss
-
Participants receiving 2.4 mg once weekly lost up to 15% of baseline body weight over 68 weeks.
-
Appetite suppression and slower gastric emptying were key contributing mechanisms.
3. Cardiovascular Benefits
-
Semaglutide significantly reduces major adverse cardiovascular events (MACE) such as nonfatal stroke and myocardial infarction in patients with existing cardiovascular risk.
4. Liver and Inflammation Markers
-
Studies also indicate a reduction in alanine transaminase (ALT) and C-reactive protein (CRP), suggesting potential hepatic and anti-inflammatory benefits.
Dosing and Titration
-
Route: Subcutaneous injection
-
Frequency: Once weekly
Recommended Titration Protocol (Based on Available Studies):
Gradual titration is critical to improving tolerability and minimizing gastrointestinal side effects.
-
Titration reduces side effects and enhances tolerability.
-
Doses above 2.0 mg are typically used for obesity and chronic weight management.
Risks
While generally well-tolerated in published trials, the following side effects were reported.
Note: This is not an exhaustive safety profile and reflects only publicly published, limited studies.
-
Gastrointestinal effects: Nausea, vomiting, constipation, and diarrhea are most common and dose-dependent.
-
Gallbladder-related issues: Cases of gallstones and cholecystitis have been reported.
-
Pancreatitis: Rare but documented in GLP-1 receptor agonist use.
-
Thyroid C-cell tumors: Observed in rodent studies—human relevance is still under investigation.
-
Discontinuation Rate: Approximately 5–10% due to tolerability issues.
References
-
Efficacy and safety of once-weekly semaglutide 2.4 mg vs placebo as an adjunct to intensive behavioral therapy in adults with overweight or obesity (STEP 3): a randomized, double-blind, controlled trial
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8736331/ -
Effects of once-weekly semaglutide on kidney function and albuminuria in people with overweight or obesity: a post hoc analysis of the STEP 1, 2, and 4 trials
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215664/ -
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294388/ -
Once-weekly semaglutide in adolescents with obesity
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159769/ -
Gastrointestinal adverse events of GLP-1 receptor agonists: A systematic review and network meta-analysis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338217/ -
Semaglutide for the treatment of obesity: a review
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12039506/